A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer

European Journal of Surgical Oncology

Volumn 36, Issue 3, 2010, Pages 244-250

  Velenik, V ^a   Ocvirk, J ^a   Oblak, I ^a   Anderluh, F ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Capecitabine; Cetuximab; Neoadjuvant chemoradiotherapy; Rectal cancer

Indexed keywords

CAPECITABINE; CETUXIMAB;

ACNE; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANUS SPHINCTER; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTITIS; DIARRHEA; DRUG HYPERSENSITIVITY; DRY SKIN; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; INFECTION; LEUKOPENIA; LIVER TOXICITY; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIATION DERMATITIS; RASH; RECTUM CANCER; RECTUM SURGERY; SEPSIS; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLECTOMY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PRODRUGS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 76449085548     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2009.12.002     Document Type: Article

References (30)

1. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345 9 (2001) 638-646
2. Camma C., Giunta M., Fiorica F., Pagliaro L., Craxi A., and Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284 8 (2000) 1008-1015
3. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 358 9290 (2001) 1291-1304
4. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331 8 (1994) 502-507
5. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 17 (2004) 1731-1740
6. Gerard J.P., Conroy T., Bonnetain F., et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24 28 (2006) 4620-4625
7. Bosset J.F., Collette L., Calais G., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355 11 (2006) 1114-1123
8. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 72 1 (2004) 15-24
9. Schuller J., Cassidy J., Dumont E., et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45 4 (2000) 291-297
10. Di Costanzo F., Sdrobolini A., and Gasperoni S. Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer. Crit Rev Oncol Hematol 35 2 (2000) 101-108
11. Sawada N., Ishikawa T., Sekiguchi F., Tanaka Y., and Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5 10 (1999) 2948-2953
12. Kim J.C., Kim T.W., Kim J.H., et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 63 2 (2005) 346-353
13. Velenik V., Anderluh F., Oblak I., Strojan P., and Zakotnik B. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J 47 5 (2006) 693-700
14. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., and Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7 4 (2005) 301-311
15. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., and Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 11 (1995) 1311-1318
16. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 14 (2009) 1408-1417
17. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27 5 (2009) 663-671
18. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
19. Li S., Kim J.S., Kim J.M., et al. Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 65 3 (2006) 705-712
20. Bertolini F., Bengala C., Losi L., et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 68 5 (2007) 1455-1461
21. Bertolini F., Chiara S., Bengala C., et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 73 2 (2009) 466-472
22. Machiels J.P., Sempoux C., Scalliet P., et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 18 4 (2007) 738-744
23. Dworak O., Keilholz L., and Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12 1 (1997) 19-23
24. Horisberger K., Treschl A., Mai S., et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys (2009)
25. Dunst J., Reese T., Sutter T., et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20 19 (2002) 3983-3991
26. Willeke F., Horisberger K., Kraus-Tiefenbacher U., et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 96 6 (2007) 912-917
27. Carlomagno C., Farella A., Bucci L., et al. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 20 (2009) 906-912
28. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the mercury study. Radiology 243 (2007) 132-139
29. Bengala C., Bettelli S., Bertolini F., et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 20 3 (2009) 469-474
30. Debucquoy A., Haustermans K., Daemen A., et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 27 17 (2009) 2751-2757